Pharmaceutical Counterfeiting

Paper Summary:

This paper explains that counterfeiting is a huge problem for the pharmaceutical industry because it relates to direct liability. The author points out that some companies are using a security triangle, which is a three-tiered approach to security measures in packaging: An overt features such as holograms, deterrents on currency such as pen reactive inks and activities in the arena of forensic technology. The paper states that, the FDA has postponed implementation of federal drug pedigree rules three times since first calling for it in the 1987 Prescription Drug Marketing Act (PDMA).

From the Paper:

"This problem becomes even more complicated when introducing online sales of prescription products. How is it possible to make sure that the authentic product is being purchased, plus at the right quantity and correct price? Another problem is buying from other countries. In July 2004, according to a report issued by the FDA, counterfeit versions of Merck s cholesterol medication Zocor (simvastatin), as well as carisoprodol, a genetic muscle relaxer, were imported from Mexico by Americans looking for cheap prescription drugs. Tests on the drugs, however, showed the counterfeit Zocor did not contain any active ingredients, and the counterfeit carisoprodol differed in potency compared with the authentic product."

More papers on Pharmaceutical Counterfeiting:

• Research Paper # 95219 : "Importing Pharmaceutical Drugs"
• Essay # 16459 : "Pharmaceuticals in Russia"
• Research Paper # 75730 : "Counterfeit Drugs"

APA Citation:

MLA Citation: